文献速递乳腺癌

血液生物标志物用于乳腺癌早期检测的未来

The future of blood-based biomarkers for the early detection of breast cancer.
PubMed 文献 · Eur J Cancer · 2018-02-06

综述讨论乳腺癌筛查中乳腺X线摄影的假阳性、假阴性和过度诊断问题,提出血液生物标志物作为非侵入性替代策略。蛋白质、自身抗体、miRNA、核酸甲基化、代谢物和脂质等候选标志物在检测乳腺癌(包括浸润前和早期阶段)方面显示潜力,但血液标志物筛查仍处于早期开发阶段,临床和临床前问题有待解决。

要点

  • 乳腺X线摄影存在假阳性、假阴性和过度诊断,需可靠、可及、经济的筛查标志物。
  • 蛋白质、自身抗体、miRNA、核酸甲基化、代谢物和脂质等血液标志物显示检测潜力。
  • 血液标志物用于乳腺癌筛查仍处早期开发阶段,临床转化前需解决多项问题。

核心结论

  • 血液生物标志物是有潜力的非侵入性乳腺癌筛查策略,但尚处于早期开发阶段,未达到临床可用水平。

研究设计与样本

  • 综述总结了血液生物标志物作为乳腺癌筛查工具的最新发现,并讨论其局限性与挑战。

主要发现

  • 蛋白质、自身抗体、miRNA、核酸甲基化、代谢物和脂质等候选标志物在检测乳腺癌(包括浸润前和早期阶段)方面显示潜力。
  • 目前使用的血液生物标志物均不够敏感,不足以用于乳腺癌早期检测。

临床怎么用

  • 血液标志物目前不应用于常规乳腺癌筛查,需等待临床和临床前问题解决。

局限性

  • 血液生物标志物用于乳腺癌筛查仍处早期开发阶段,多种临床和临床前问题有待解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer (BC) is the most frequently diagnosed cancer and the most common cause of cancer-related mortality among women worldwide. Despite the extensive use of mammography as the gold standard for BC screening, the occurrences of false-positive and false-negative mammograms, as well as overdiagnosis, remain a concern in breast oncology. Thus, there is a need to identify reliable biomarkers from an easily accessible source that could generate cost-effective assays feasible for routine screening. Blood-based biomarkers may offer an alternative non-invasive strategy to improve cancer screening. Although none of the currently used blood-based biomarkers are sensitive enough for the early detection of BC, a plethora of significant findings pertaining to the development of screening tools using blood-based biomarkers have emerged in recent years. Promising candidate biomarkers such as proteins, autoantibodies, miRNAs, nucleic acid methylation, metabolites and lipids have shown great potential for detecting BC, including detection at the pre-invasive and early stages of the disease. Nevertheless, blood-based biomarkers for BC screening are still at the early phases of development, and various clinical and preclinical issues need to be addressed before these biomarkers can be used clinically. This review summarises the latest discoveries for harnessing blood-based biomarkers as novel BC screening tools, as well as discusses the limitations and challenges that need to be overcome before the translation of their use from the bench to the bedside.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer. 2018. PMID: 29413690. doi:10.1016/j.ejca.2017.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。